Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Analysis: How The Industry Is Evolving Toward A $3.43 Billion Future

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

The arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market has experienced rapid expansion in recent years. This market is projected to grow from $1.52 billion in 2025 to $1.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.5%. The historical growth of the market can be attributed to the expansion of functional genomics research, the availability of crispr editing reagents, the increase in academic screening programs, the early adoption of arrayed screening formats, and the rising use of cell-based assays.

The arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market is projected to experience substantial expansion over the coming years, with its valuation anticipated to reach $3.43 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.7%. This growth trajectory within the forecast period is fueled by factors such as the heightened demand for precision drug discovery, increased investment in gene therapy research, the broadening of disease modeling applications, the expanding adoption of bioinformatics-driven screening methods, and stronger collaborations between academic institutions and industrial entities. Key trends expected during this period involve a surge in demand for targeted gene validation screens, the escalating utilization of high-throughput arrayed crispr assays, the deeper integration of phenotypic data analytics, the broadened availability of custom crispr screening services, and a heightened emphasis on the accuracy of functional genomics.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=40849201&type=smp&name=Arrayed%20Clustered%20Regularly%20Interspaced%20Short%20Palindromic%20Repeats%20%28CRISPR%29%20Screening%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Growth Backed By Core Demand Fundamentals

The expanding focus on personalized medicine is projected to drive the growth of the arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market. Personalized medicine represents a healthcare strategy that customizes treatment and prevention plans according to an individual’s genetic, biological, and lifestyle attributes. Its adoption is increasing due to advancements in genomics and molecular diagnostics, allowing treatments to be tailored to a person’s genetic profile for improved outcomes. Arrayed CRISPR screening supports personalized medicine by systematically testing the impact of specific gene edits on individual cell responses. This facilitates the identification of patient-specific drug targets, the prediction of treatment responses, and the development of customized therapies based on a person’s genetic and cellular profile. For example, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a rise from six in 2022. The new personalized treatments approved in 2023 also included seven cancer drugs and three for other diseases and conditions. Consequently, the heightened emphasis on personalized medicine is fueling the growth of the arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market.

Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Segment Trends And Revenue Contributors

The arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market covered in this report is segmented –

1) By Product Type: Clustered Regularly Interspaced Short Palindromic Repeats Libraries; Reagents And Consumables; Instruments; Software And Services

2) By Application: Functional Genomics; Drug Discovery; Disease Modeling; Gene Validation; Other Applications

3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Research Organizations; Other End Users

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats Libraries: Genome Wide Knockout Libraries; Targeted Gene Libraries; Activation Libraries; Repression Libraries; Custom Designed Libraries

2) By Reagents And Consumables: Guide Ribonucleic Acid Reagents; Cas Enzyme Reagents; Transfection Reagents; Cell Culture Reagents; Assay And Detection Reagents

3) By Instruments: Automated Liquid Handling Systems; High Throughput Screening Systems; Cell Imaging Systems; Flow Cytometry Instruments; Genomic Analysis Instruments

4) By Software And Services: Screening Design Software; Data Analysis Software; Bioinformatics Services; Screening Execution Services; Custom Assay Development Services

Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Growth Trends Reshaping The Competitive Landscape

Major entities operating within the CRISPR screening market are increasingly engaging in strategic partnerships to elevate the precision of high-throughput phenotypic screening. A strategic partnership is defined as a formal collaborative effort where organizations combine their assets, knowledge, or technologies to accomplish shared objectives, leading to accelerated innovation, diminished risk, and a broader market reach without necessitating a merger or acquisition. For example, in November 2023, AstraZeneca Plc, a UK-based science-focused biopharmaceutical company, collaborated with the Medical Research Council (MRC), a UK government agency, and the Milner Therapeutics Institute (MTI) at the University of Cambridge, a UK biomedical research institute, to launch the Functional Genomics Screening Laboratory (FGSL). This state-of-the-art facility aims to advance drug discovery by charting gene-phenotype connections in chronic conditions like cardiovascular and metabolic disorders, thus reinforcing UK genomics leadership through open academic partnerships. Key advantages include high-throughput automation for accurate imaging and phenotyping in organoids or iPSCs, which is superior to pooled approaches, as well as offering free access to researchers, faster target validation, and shared expertise to accelerate the development of therapies.

Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Leading Players And Competitive Positioning

Major companies operating in the arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market are Thermo Fisher Scientific Inc, Merck KGaA, GE HealthCare Technologies Inc, Applied Biological Materials Inc, Agilent Technologies Inc, Charles River Laboratories International Inc, Integrated DNA Technologies Inc, GenScript Biotech Corporation, Synthego Holdings LLC, Santa Cruz Biotechnology Inc, Creative Biolabs Inc, VectorBuilder Inc, Admera Health LLC, Addgene Inc, Ncardia, BioCat GmbH, Cellecta Inc, GeneCopoeia Inc, Creative Biogene Inc, and Aelian Biotechnology.

View The Full Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Report:

https://thebusinessresearchcompany.com/report/arrayed-clustered-regularly-interspaced-short-palindromic-repeats-crispr-screening-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Regional Distribution: Which Areas Power Market Growth?

North America was the largest region in the arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arrayed clustered regularly interspaced short palindromic repeats (crispr) screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model